NASDAQ:SBFM - Nasdaq - US8677817004 - Common Stock - Currency: USD
NASDAQ:SBFM (2/21/2025, 8:00:01 PM)
2.45
-0.02 (-0.81%)
The current stock price of SBFM is 2.45 USD. In the past month the price decreased by -14.93%. In the past year, price decreased by -97.67%.
Symbol | Name | TA | FA | PE | Market Cap |
---|---|---|---|---|---|
ABBV | ABBVIE INC | 19.97 | 357.10B | ||
AMGN | AMGEN INC | 15.29 | 162.72B | ||
GILD | GILEAD SCIENCES INC | 23.85 | 137.00B | ||
VRTX | VERTEX PHARMACEUTICALS INC | 1669.79 | 124.40B | ||
REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.56B | ||
ARGX | ARGENX SE - ADR | N/A | 39.16B | ||
ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 32.32B | ||
BNTX | BIONTECH SE-ADR | N/A | 28.77B | ||
ONC | BEIGENE LTD-ADR | N/A | 27.25B | ||
NTRA | NATERA INC | N/A | 21.43B | ||
BIIB | BIOGEN INC | 8.54 | 20.49B | ||
SMMT | SUMMIT THERAPEUTICS INC | N/A | 16.31B |
Sunshine Biopharma Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Fort Lauderdale, Florida and currently employs 44 full-time employees. The company went IPO on 2008-08-15. Sunshine Biopharma, Inc. is a Canada-based pharmaceutical company. The firm offers and researches life-saving medicines in a variety of therapeutic areas, including oncology and antivirals. The firm has over 32 additional generic prescription drugs. In addition, the Company is conducting a proprietary drug development program which consists of K1.1 mRNA, an mRNA-Lipid Nanoparticle targeted for liver cancer, and PLpro protease inhibitor, a small molecule for treatment of SARS Coronavirus infections. The firm operates through two segments: Prescription Generic Pharmaceuticals (Generic Pharmaceuticals) and Nonprescription Over-The-Counter Products (OTC Products). The company also operates two wholly owned subsidiaries: NoraPharma Inc., which has a portfolio of pharmaceutical products consisting of approximately 61 generic prescription drugs on the market in Canada, and Sunshine Biopharma Canada Inc., which develops and sells non-prescription over-the-counter (OTC) products.
SUNSHINE BIOPHARMA INC
333 Las Olas Way, Cu4 Suite 433
FORT LAUDERDALE FLORIDA US
Employees: 44
Company Website: https://www.sunshinebiopharma.com/
Investor Relations: http://www.sunshinebiopharma.com/sec-filings.html
Phone: 19545150810
The current stock price of SBFM is 2.45 USD. The price decreased by -0.81% in the last trading session.
The exchange symbol of SUNSHINE BIOPHARMA INC is SBFM and it is listed on the Nasdaq exchange.
SBFM stock is listed on the Nasdaq exchange.
7 analysts have analysed SBFM and the average price target is 306 USD. This implies a price increase of 12389.8% is expected in the next year compared to the current price of 2.45. Check the SUNSHINE BIOPHARMA INC stock analysts ratings, price target forecast and up-and down grades for more detailed information.
SUNSHINE BIOPHARMA INC (SBFM) has a market capitalization of 4.90M USD. This makes SBFM a Nano Cap stock.
SUNSHINE BIOPHARMA INC (SBFM) currently has 44 employees.
SUNSHINE BIOPHARMA INC (SBFM) has a resistance level at 2.58. Check the full technical report for a detailed analysis of SBFM support and resistance levels.
The Revenue of SUNSHINE BIOPHARMA INC (SBFM) is expected to grow by 67.82% in the next year. Check the estimates tab for more information on the SBFM EPS, Sales, EBIT and EBITDA future analyst estimates.
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
SBFM does not pay a dividend.
SUNSHINE BIOPHARMA INC (SBFM) will report earnings on 2025-03-26, before the market open.
SUNSHINE BIOPHARMA INC (SBFM) does not have a PE ratio as the earnings reported over the last twelve months were negative (-150.88).
The outstanding short interest for SUNSHINE BIOPHARMA INC (SBFM) is 4.19% of its float. Check the ownership tab for more information on the SBFM short interest.
ChartMill assigns a fundamental rating of 4 / 10 to SBFM. SBFM scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
Over the last trailing twelve months SBFM reported a non-GAAP Earnings per Share(EPS) of -150.88. The EPS increased by 84.76% compared to the year before.
Industry Rank | Sector Rank | ||
---|---|---|---|
PM (TTM) | N/A | ||
ROA | -14.06% | ||
ROE | -16.88% | ||
Debt/Equity | 0 |
ChartMill assigns a Buy % Consensus number of 83% to SBFM. The Buy consensus is the average rating of analysts ratings from 7 analysts.
For the next year, analysts expect an EPS growth of 98.71% and a revenue growth 67.82% for SBFM